Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03130959 : An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies
PhasePhase 2
AgesMin: 6 Months Max: 21 Years
Eligibility
Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

- Children and adolescents diagnosed with either:

- Diffuse Intrinsic Pontine Glioma (DIPG), in first-line, after completion of standard
radiotherapy

- High Grade Glioma (HGG), recurrent or progressive

- Medulloblastoma, recurrent or progressive

- Ependymoma, recurrent or progressive

- Other high-grade tumors of the central nervous system, recurrent or progressive

- Lansky play score (LPS) for =< 16 years of age or Karnofsky performance scale (KPS)
for > 16 years of age assessed within two weeks of enrollment must be >= 60

- A tumor sample must be available for submission to central laboratory [not required
for DIPG]

Exclusion Criteria:

- Participants with active, known or suspected autoimmune disease

- Participants unable to taper steroids due to ongoing mass effect

- Participants with low-grade gliomas or tumors of unknown malignant potential

- Prior treatment with any drug that targets T cell co-stimulation pathways (such as
checkpoint inhibitors)

Other protocol defined inclusion/exclusion criteria could apply
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03130959      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740